Sodium–Glucose Co-transporter 2 Inhibitors in Heart Failure: Recent Data and Implications for Practice

Heart failure is a shared chronic phase of many cardiac diseases and its prevalence is on the rise globally. Previous large-scale cardiovascular outcomes trials of sodium–glucose co-transporter 2 (SGLT2) inhibitors in patients with type 2 diabetes (T2D) have suggested that these agents may help to p...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Giuseppe Rosano, David Quek, Felipe Martínez
Format: article
Langue:EN
Publié: Radcliffe Medical Media 2020
Sujets:
Accès en ligne:https://doaj.org/article/58046a30dfdd462285494bac6b076e2c
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!